Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to UCSF for Phase 1 Trial of Psilocybin in Healthy Older Adults with Low Well-Being
Filament has shipped PEX010 to the University of California, San Francisco (UCSF) for OAD1, a Phase 1 trial of psilocybin in healthy older adults with low well-being.Toronto, Ontario--(Newsfile Corp. - November 17, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Through its wholly owned subsidiary Filament Health Corp. ("Filament"), the...